Pål Rongved

Pål Rongved is a Professor in Medicinal Chemistry at the Department of Pharmacy, University of Oslo, with a career spanning academia and industry. His research focuses on medicinal chemistry, antibiotic resistance, AML therapy, and metal-chelating drug design.

• Key affiliations: Director at Patias Innovation Ltd, Innovation Advisor roles (2003-2011), and EU COST network ZINC-NET (2012–present).
• Education: Dr. Philos. (2000), Cand.scient. in Organic Chemistry (1981), Master of Arts (1978), all from University of Oslo.

His research interests integrate drug discovery, organic synthesis, and bioactive compound development across:

• Antibiotics (linked to the ZinChel project)
• Antiviral agents targeting SARS-CoV
• AML therapies (acute myeloid leukemia)
• LXR receptor modulators for metabolic diseases
• Aquaporin regulation via zinc complexing agents

Scientific contributions include zinc-chelating compounds to reverse carbapenem resistance, cyclodextrin-based solubility enhancement for drugs, and oxysterol mimics for nuclear receptor modulation. Collaborations span Adjutec Pharma AS, CIME, and SYNPHASE.